{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:58:43Z","timestamp":1792263523094,"version":"4.4.0"},"reference-count":108,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV) constitutes a very common pathogen and a well-characterized carcinogen. EBV has the ability to establish a chronic latent infection, during which only a subset of the viral genes is expressed. EBV is implicated in multiple malignancies, including Hodgkin\u2019s lymphoma (HL). HL mainly affects adolescents and young adults and has an overall favorable prognosis. However, relapsed or refractory disease still poses a therapeutic challenge. EBV does not only induce malignant transformation but also hinders the detection and clearance of the neoplastic cells by the immune system. The proteins and non-coding RNAs expressed in latency IIa, which is associated with HL, employ a variety of mechanisms to target different steps of innate and adaptive immunity, to take advantage of the immunosuppressant effect of immune checkpoints, and to shape the microenvironment to support the survival and proliferation of malignant cells. They suppress the expression or promote the degradation of pattern-recognition receptors, interfere with type I interferon and proinflammatory cytokine mediated signaling, and hinder the effector function of natural killer cells. The processing and presentation of peptides to CD4 and CD8 T cells are also hampered. EBV induces the expression of immune checkpoints, the secretion of immunosuppressive cytokines, and the efflux of regulatory T cells in the tumor microenvironment. The current review provides a comprehensive overview of the molecular mechanisms underlying this complex interplay between EBV and the immune system in HL with focus on clinical data from the pediatric population, which is the key for developing novel, effective therapeutic interventions.<\/jats:p>","DOI":"10.3390\/cancers17091481","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:21:31Z","timestamp":1745817691000},"page":"1481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epstein\u2013Barr Infection, Hodgkin\u2019s Lymphoma, and the Immune System: Insights into the Molecular Mechanisms Facilitating Immune Evasion"],"prefix":"10.3390","volume":"17","author":[{"given":"Eleni","family":"Tsotridou","sequence":"first","affiliation":[{"name":"Children\u2019s and Adolescents\u2019 Hematology Oncology Unit, 2nd Department of Paediatrics, AHEPA University General Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, St. Kyriakidi 1, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-2970","authenticated-orcid":false,"given":"Emmanouel","family":"Hatzipantelis","sequence":"additional","affiliation":[{"name":"Children\u2019s and Adolescents\u2019 Hematology Oncology Unit, 2nd Department of Paediatrics, AHEPA University General Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, St. Kyriakidi 1, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A Review of Human Carcinogens\u2014Part B: Biological Agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Smatti, M.K., Al-Sadeq, D.W., Ali, N.H., Pintus, G., Abou-Saleh, H., and Nasrallah, G.K. (2018). Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00211"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Shannon-Lowe, C., and Rickinson, A. (2019). The Global Landscape of EBV-Associated Tumors. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00713"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1107\/S0907444906030034","article-title":"Structural Genomics of the Epstein-Barr Virus","volume":"62","author":"Tarbouriech","year":"2006","journal-title":"Biol. Crystallogr."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kong, I.Y., and Giulino-Roth, L. (2024). Targeting Latent Viral Infection in EBV-Associated Lymphomas. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1342455"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas","volume":"350","author":"Gross","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg Cells in Hodgkin\u2019s Disease Represent the Outgrowth of a Dominant Tumor Clone Derived from (Crippled) Germinal Center B Cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_9","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2025, February 27). SEER*Stat Database: Incidence\u2014SEER Research Data, 8 Registries, Nov 2023 Sub (1975\u20132021)\u2014Linked To County Attributes\u2014Time Dependent (1990\u20132022) Income\/Rurality, 1969\u20132022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2024, Based on the November 2023 Submission, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101674","DOI":"10.1016\/j.eclinm.2022.101674","article-title":"Lymphomas Associated with Epstein-Barr Virus Infection in 2020: Results from a Large, Unselected Case Series in France","volume":"54","author":"Donzel","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17305\/bjbms.2007.3092","article-title":"Association of Hodgkin\u2019s Lymphoma with Epstein Barr Virus Infection","volume":"7","year":"2007","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.leu.2401097","article-title":"Epstein-Barr Virus and Hodgkin\u2019s Disease: Further Evidence for the Three Disease Hypothesis","volume":"12","author":"Armstrong","year":"1998","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent Membrane Protein 1 of Epstein-Barr Virus Interacts with JAK3 and Activates STAT Proteins","volume":"18","author":"Gires","year":"1999","journal-title":"EMBO J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1073\/pnas.94.4.1447","article-title":"The Epstein-Barr Virus LMP1 Amino Acid Sequence That Engages Tumor Necrosis Factor Receptor Associated Factors Is Critical for Primary B Lymphocyte Growth Transformation","volume":"94","author":"Izumi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/fvl-2018-0120","article-title":"The Epstein-Barr Virus LMP1 Interactome: Biological Implications and Therapeutic Targets","volume":"13","author":"Cheerathodi","year":"2018","journal-title":"Future Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An Etiological Role for the Epstein-Barr Virus in the Pathogenesis of Classical Hodgkin Lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/08830180109045591","article-title":"The Effects of the Epstein-Barr Virus Latent Membrane Protein 2A on B Cell Function","volume":"20","author":"Merchant","year":"2001","journal-title":"Int. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/v5010226","article-title":"Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus","volume":"5","author":"Sugden","year":"2013","journal-title":"Viruses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.12768","article-title":"Treatment Outcome in Children and Adolescents with Relapsed Hodgkin Lymphoma--Results of the UK HD3 Relapse Treatment Strategy","volume":"165","author":"Shankar","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.21037\/atm.2019.05.58","article-title":"Immunotherapy and Targeted Therapy\u2014The New Roadmap in Cancer Treatment","volume":"7","author":"Shahid","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.4161\/21645515.2014.979640","article-title":"Mechanisms and Pathways of Innate Immune Activation and Regulation in Health and Cancer","volume":"10","author":"Cui","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen Recognition and Innate Immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.4049\/jimmunol.0903459","article-title":"EBV Latent Membrane Protein 1 Is a Negative Regulator of TLR9","volume":"185","author":"Fathallah","year":"2010","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Xu, C., Sun, L., Liu, W., and Duan, Z. (2018). Latent Membrane Protein 1 of Epstein-Barr Virus Promotes RIG-I Degradation Mediated by Proteasome Pathway. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01446"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11638","DOI":"10.1128\/JVI.01570-06","article-title":"The Epstein-Barr Virus-Encoded LMP-1 Oncoprotein Negatively Affects Tyk2 Phosphorylation and Interferon Signaling in Human B Cells","volume":"80","author":"Geiger","year":"2006","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-Inducible Antiviral Effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1038\/onc.2009.249","article-title":"The EBV-Encoded Latent Membrane Proteins, LMP2A and LMP2B, Limit the Actions of Interferon by Targeting Interferon Receptors for Degradation","volume":"28","author":"Shah","year":"2009","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhang, X., Li, Z., Peng, Q., Liu, C., Wu, Y., Wen, Y., Zheng, R., Xu, C., Tian, J., and Zheng, X. (2024). Epstein-Barr Virus Suppresses N(6)-Methyladenosine Modification of TLR9 to Promote Immune Evasion. J. Biol. Chem., 300.","DOI":"10.1016\/j.jbc.2024.107226"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Westhoff Smith, D., Chakravorty, A., Hayes, M., Hammerschmidt, W., and Sugden, B. (2021). The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells. MBio, 12.","DOI":"10.1128\/mBio.02243-21"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e03440-20","DOI":"10.1128\/mBio.03440-20","article-title":"Multiple Viral MicroRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus","volume":"12","author":"Bouvet","year":"2021","journal-title":"MBio"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000479749","article-title":"Epstein-Barr Virus MiR-BART6-3p Inhibits the RIG-I Pathway","volume":"9","author":"Lu","year":"2017","journal-title":"J. Innate Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.4049\/jimmunol.1200312","article-title":"Cutting Edge: MiR-223 and EBV MiR-BART15 Regulate the NLRP3 Inflammasome and IL-1\u03b2 Production","volume":"189","author":"Haneklaus","year":"2012","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.4049\/jimmunol.1501605","article-title":"EBV MicroRNA BART16 Suppresses Type I IFN Signaling","volume":"198","author":"Hooykaas","year":"2017","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00530-17","DOI":"10.1128\/JVI.00530-17","article-title":"An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1","volume":"91","author":"Skinner","year":"2017","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.chom.2010.03.008","article-title":"Systematic Analysis of Viral and Cellular MicroRNA Targets in Cells Latently Infected with Human Gamma-Herpesviruses by RISC Immunoprecipitation Assay","volume":"7","author":"Malterer","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1534\/genetics.109.107540","article-title":"Identification of Novel Genes That Mediate Innate Immunity Using Inbred Mice","volume":"183","author":"Yang","year":"2009","journal-title":"Genetics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fan, J., Li, Q., Liang, J., Chen, Z., Chen, L., Lai, J., and Chen, Q. (2023). Regulation of IFN\u03b2 Expression: Focusing on the Role of Its Promoter and Transcription Regulators. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1158777"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chom.2009.03.003","article-title":"Diverse Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to Escape Recognition by Natural Killer Cells","volume":"5","author":"Nachmani","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cti2.1230","article-title":"NKG2D and MICA\/B Shedding: A \u201ctag Game\u201d between NK Cells and Malignant Cells","volume":"9","author":"Xing","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_42","first-page":"355","article-title":"Immune Evasion by Epstein-Barr Virus","volume":"391","author":"Ressing","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1182\/blood-2009-02-203687","article-title":"Discerning Regulation of Cis- and Trans-Presentation of CD8+ T-Cell Epitopes by EBV-Encoded Oncogene LMP-1 through Self-Aggregation","volume":"113","author":"Smith","year":"2009","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"\u0160imi\u010di\u0107, P., Batovi\u0107, M., Stojanovi\u0107 Markovi\u0107, A., and \u017didovec-Lepej, S. (2024). Deciphering the Role of Epstein-Barr Virus Latent Membrane Protein 1 in Immune Modulation: A Multifaced Signalling Perspective. Viruses, 16.","DOI":"10.3390\/v16040564"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.4049\/jimmunol.179.12.8225","article-title":"Latent Membrane Protein 1 of EBV Activates Phosphatidylinositol 3-Kinase to Induce Production of IL-10","volume":"179","author":"Lambert","year":"2007","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.158.9.4045","article-title":"Involvement of IL-10 in the Autonomous Growth of EBV-Transformed B Cell Lines","volume":"158","author":"Beatty","year":"1997","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood.V90.6.2390","article-title":"Downregulation of TAP1 in B Lymphocytes by Cellular and Epstein-Barr Virus-Encoded Interleukin-10","volume":"90","author":"Zeidler","year":"1997","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 Directly Inhibits CD8(+) T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/10428194.2019.1607330","article-title":"Epstein-Barr Virus-Encoded LMP1 Induces Ectopic CD137 Expression on Hodgkin and Reed-Sternberg Cells via the PI3K-AKT-MTOR Pathway","volume":"60","author":"Aravinth","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1160188","DOI":"10.1080\/2162402X.2016.1160188","article-title":"CD137 Signaling in Hodgkin and Reed-Sternberg Cell Lines Induces IL-13 Secretion, Immune Deviation and Enhanced Growth","volume":"5","author":"Rajendran","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood-2014-08-594689","article-title":"Epstein-Barr Virus LMP2A Suppresses MHC Class II Expression by Regulating the B-Cell Transcription Factors E47 and PU.1","volume":"125","author":"Lin","year":"2015","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","article-title":"Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances IL-10 Production through the Activation of Bruton\u2019s Tyrosine Kinase and STAT3","volume":"500","author":"Incrocci","year":"2017","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rancan, C., Schirrmann, L., H\u00fcls, C., Zeidler, R., and Moosmann, A. (2015). Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004906"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/375685a0","article-title":"Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1","volume":"375","author":"Levitskaya","year":"1995","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.1088902","article-title":"Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1","volume":"301","author":"Yin","year":"2003","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Apcher, S., Daskalogianni, C., Manoury, B., and F\u00e5hraeus, R. (2010). Epstein Barr Virus-Encoded EBNA1 Interference with MHC Class I Antigen Presentation Reveals a Close Correlation between MRNA Translation Initiation and Antigen Presentation. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001151"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"30090","DOI":"10.1074\/jbc.M803290200","article-title":"Gly-Ala Repeats Induce Position- and Substrate-Specific Regulation of 26 S Proteasome-Dependent Partial Processing","volume":"283","author":"Daskalogianni","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e01941-18","DOI":"10.1128\/mBio.01941-18","article-title":"MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo","volume":"10","author":"Murer","year":"2019","journal-title":"MBio"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1084\/jem.20160248","article-title":"Epstein-Barr Viral MiRNAs Inhibit Antiviral CD4+ T Cell Responses Targeting IL-12 and Peptide Processing","volume":"213","author":"Tagawa","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","article-title":"Epstein-Barr Virus MicroRNAs Reduce Immune Surveillance by Virus-Specific CD8+ T Cells","volume":"113","author":"Albanese","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1871525719666210510171132","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives","volume":"20","author":"Tsotridou","year":"2022","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/etm.2023.12294","article-title":"Expression of the Immune Checkpoint Molecules PD-L1 and PD-1 in EBV-associated Lymphoproliferative Disorders: A Meta-analysis","volume":"27","author":"Yu","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2019000889","article-title":"EBV MicroRNA-BHRF1-2-5p Targets the 3\u2032UTR of Immune Checkpoint Ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological Analysis Reveals a PD-L1-Associated Microenvironmental Niche for Reed-Sternberg Cells in Hodgkin Lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_69","first-page":"99","article-title":"CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation","volume":"410","author":"Chikuma","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ma, S.-D., Xu, X., Jones, R., Delecluse, H.-J., Zumwalde, N.A., Sharma, A., Gumperz, J.E., and Kenney, S.C. (2016). PD-1\/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005642"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel Immune Checkpoint Targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by Tumor-Infiltrating Lymphocytes Is Coincident with the Suppression of Latent Membrane Antigen-Specific CD8+ T-Cell Function in Hodgkin Lymphoma Patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e27571","DOI":"10.1002\/pbc.27571","article-title":"Expression of PD-1\/PD-L1 in Children\u2019s Classical Hodgkin Lymphomas","volume":"66","author":"Aladjidi","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e27757","DOI":"10.1002\/pbc.27757","article-title":"PD-L1 Expression in Pediatric Epstein-Barr Virus Positive Classic Hodgkin Lymphoma Is Not Associated with 9p24.1 Amplification","volume":"66","author":"Uccini","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Jimenez, O., Mangiaterra, T., Colli, S., Garc\u00eda Lombardi, M., Preciado, M.V., De Matteo, E., and Chabay, P. (2022). PD-1 and LAG-3 Expression in EBV-Associated Pediatric Hodgkin Lymphoma Has Influence on Survival. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.957208"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular Biology of Hodgkin Lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Georgoulis, V., Papoudou-Bai, A., Makis, A., Kanavaros, P., and Hatzimichael, E. (2023). Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications. Biology, 12.","DOI":"10.20944\/preprints202305.1213.v1"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e27307","DOI":"10.1002\/pbc.27307","article-title":"Flow Cytometry for Assessment of the Tumor Microenvironment in Pediatric Hodgkin Lymphoma","volume":"65","author":"Henry","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez, V., Sol\u00f3rzano, J.L., Garc\u00eda-Cos\u00edo, M., Alonso-Alonso, R., Rodr\u00edguez, M., Cereceda, L., Fern\u00e1ndez, S., D\u00edaz, E., Montalb\u00e1n, C., and Est\u00e9vez, M. (2024). Immune and Stromal Transcriptional Patterns That Influence the Outcome of Classic Hodgkin Lymphoma. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-51376-1"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed\/Refractory Hodgkin Lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00262-020-02787-2","article-title":"Epstein-Barr Virus Recruits PDL1-Positive Cells at the Microenvironment in Pediatric Hodgkin Lymphoma","volume":"70","author":"Jimenez","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjh.12980","article-title":"Epstein-Barr Virus Infection Induces an Increase of T Regulatory Type 1 Cells in Hodgkin Lymphoma Patients","volume":"166","author":"Morales","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","article-title":"Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin\u2019s Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells","volume":"173","author":"Baumforth","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive Regulatory T Cells Are Abundant in the Reactive Lymphocytes of Hodgkin Lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.exphem.2007.01.030","article-title":"The Relationships between Epstein-Barr Virus Latent Membrane Protein 1 and Regulatory T Cells in Hodgkin\u2019s Lymphoma","volume":"35","author":"Marshall","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3960\/jslrt.23037","article-title":"Evidence for Distinct Mechanisms of Immune Suppression in EBV-Positive and EBV-Negative Hodgkin Lymphoma","volume":"63","author":"Adam","year":"2023","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Pavlovi\u0107, A., Miljak, A., Brzica, K., and Glavina Durdov, M. (2024). The Abundance of FOXP3, FOXP3\/CD4 and CD8 Cells in the Microenvironment of Nodular Sclerosis and Mixed Cellularity Subtypes Is Associated with the Epstein-Barr Virus Status of Classic Hodgkin Lymphoma. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081680"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Jimenez, O., Barros, M.H., De Matteo, E., Garcia Lombardi, M., Preciado, M.V., Niedobitek, G., and Chabay, P. (2019). M1-like Macrophage Polarization Prevails in Young Children with Classic Hodgkin Lymphoma from Argentina. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49015-1"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Barros, M.H.M., Segges, P., Vera-Lozada, G., Hassan, R., and Niedobitek, G. (2015). Macrophage Polarization Reflects T Cell Composition of Tumor Microenvironment in Pediatric Classical Hodgkin Lymphoma and Has Impact on Survival. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124531"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Vistarop, A., Jimenez, O., Cohen, M., De Matteo, E., Preciado, M.V., and Chabay, P. (2020). Differences in Epstein-Barr Virus Characteristics and Viral-Related Microenvironment Could Be Responsible for Lymphomagenesis in Children. Pathogens, 9.","DOI":"10.3390\/pathogens9010068"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Choe, J.-Y., Yun, J.Y., Jeon, Y.K., Kim, S.H., Park, G., Huh, J.R., Oh, S., and Kim, J.E. (2014). Indoleamine 2,3-Dioxygenase (IDO) Is Frequently Expressed in Stromal Cells of Hodgkin Lymphoma and Is Associated with Adverse Clinical Features: A Retrospective Cohort Study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-335"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00262-012-1234-4","article-title":"The Specific Targeting of Immune Regulation: T-Cell Responses against Indoleamine 2,3-Dioxygenase","volume":"61","author":"Andersen","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ijc.27314","article-title":"Tumor Microenvironment Composition in Pediatric Classical Hodgkin Lymphoma Is Modulated by Age and Epstein-Barr Virus Infection","volume":"131","author":"Barros","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-12-0129","article-title":"Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact","volume":"18","author":"Barros","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_95","first-page":"e2009013","article-title":"EBV in Hodgkin Lymphoma","volume":"1","author":"Massini","year":"2009","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for Relapsed\/Refractory Classical Hodgkin Lymphoma: 5-Year Survival from the Pivotal Phase 2 CheckMate 205 Study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2018-99-111279","article-title":"Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"132","author":"Leblanc","year":"2018","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in Children and Young Adults with Relapsed or Refractory Solid Tumours or Lymphoma (ADVL1412): A Multicentre, Open-Label, Single-Arm, Phase 1\u20132 Trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin\u2019s Disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients with Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients with Relapsed Hodgkin Lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-Specific T Cells Maintain Remissions of T- and B-Cell EBV Lymphomas after Allogeneic Bone Marrow Transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.7150\/thno.26823","article-title":"EBNA1-Targeted Inhibitors: Novel Approaches for the Treatment of Epstein-Barr Virus-Associated Cancers","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses after CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Jean-Pierre, V., Lupo, J., Buisson, M., Morand, P., and Germi, R. (2021). Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.701611"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:23:04Z","timestamp":1760030584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091481"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091481","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}